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Brown-Vialetto-Van Laere Syndrome,
a Ponto-Bulbar Palsy with Deafness,
Is Caused by Mutations in C20orf54
Peter Green,1 Matthew Wiseman,1 Yanick J. Crow,3 Henry Houlden,4 Shelley Riphagen,5
Jean-Pierre Lin,6 F. Lucy Raymond,7 Anne-Marie Childs,8 Eamonn Sheridan,9 Sian Edwards,1
and Dragana J. Josifova2,*
Brown-Vialetto-Van Laere syndrome is a rare neurological disorder with a variable age at onset and clinical course. The key features are
progressive ponto-bulbar palsy and bilateral sensorineural deafness. A complex neurological phenotype with a mixed picture of upper
and lower motor neuron involvement reminiscent of amyotrophic lateral sclerosis evolves with disease progression. We identiﬁed
a candidate gene, C20orf54, by studying a consanguineous family with multiple affected individuals and subsequently demonstrated
that mutations in this gene were the cause of disease in other, unrelated families.Brown-Vialetto-Van Laere syndrome (BVVLS [MIM
211530]) was ﬁrst reported by Brown in 18941 as familial
amyotrophic lateral sclerosis (ALS [MIM 105400]) with
onset in infancy. Following the reports by Vialetto, in
1936,2 and Van Laere, in 1966,3 the name BVVLS was
adopted. The observation of recurrences in siblings in
some families suggested that the condition was probably
autosomal recessive. However, the variable age at onset
and clinical course raised the possibility that it may be etio-
logically heterogeneous and that some casesmay be caused
by a new dominant mutation.4
BVVLS is a rare disorder characterised by progressive
ponto-bulbar palsy and bilateral sensorineural hearing
loss. The disease presents with VII, IX, X, XI, andXII cranial
nerve palsies, which develop over a relatively short period
of time in a previously healthy individual. Sensorineural
hearing loss may precede the neurological signs.1–5 The
course is invariably progressive, but the rate of decline is
variable within and between families. With disease evolu-
tion, long tract signs, lower motor neuron signs, cerebellar
ataxia, and lower cranial nerve (III-VI) palsies develop,
giving rise to a complex picture resembling amyotrophic
lateral sclerosis.5,6,7,8 Diaphragmatic weakness and respira-
tory compromise are some of the most distressing features,
leading to recurrent chest infections and respiratory failure,
which are often the cause of patients’ demise.5,6
Fifty-eight cases have been documented in the literature.
Sathasivam provided a comprehensive review of the pub-
lished reports, showing a female to male prevalence of
3:1, with an apparently more severe clinical course in
males.5 The age at onset ranged from infancy to early in
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The Amerisecond decade. Hearing loss preceded the onset of neuro-
logical signs in most cases. The neurological picture,
severity, and disease duration were variable.5
The early-onset cases tend to have a much more rapid
course, lasting between 6 and 18 mo,6 but survival is pro-
longed with active management (personal observation).
The early motor milestones are usually normal. On
detailed questioning, a history of increased susceptibility
to chest infections can be elicited in some cases (personal
observation), and occasionally, the disease onset may
follow an episode of viral infection.7 The age at onset
and clinical presentation may vary within the same
family.6 Also, childhood- and adult-onset disease have
been observed in the same sibship (personal observation).
Appropriate informed consent was obtained from the
patients and guardians of the participants in this study,
in compliance with the UK National Research Ethics
Service regulation on research in human subjects. The clin-
ical details of the patients included in this report are pre-
sented in Table 1.
Initial work was undertaken on family 1. The proband
(case 1) came from a multiply consanguineous family
with several similarly affected children, who died in
infancy, strongly suggesting involvement of an auto-
somal-recessive gene. We were able to identify a stored
muscle biopsy sample from a deceased cousin (case 2),
which enabled us to undertake this study. The pedigree
could not be included for reasons of conﬁdentiality.
Case 4 was born with complex congenital heart disease.
He developed the condition at the age of 9 mo and died 18
mo later. He had a similarly affected sister whose DNA was
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Table 1. Clinical Features of Patients with BVVLS
Case Origin Consanguinity
Pre-Morbid
Status
Age at
Onset Sex
Initial
Presentation
Deafness, Age
at Diagnosis
Respiratory
Compromise, Age Associated Features Disease Duration
Family 1
Case 1 Arabic Yes Recurrent chest
infections since
age 4 mo
13 mo M Sub-acute
encephalopathy
13 mo 17 mo Hypotonia, cerebellar
signs, brisk reﬂexes in the
lower limbs, persistent
ankle clonus, stridor,
EMG: bulbar palsy,
anterior horn
involvement; phrenic
nerve denervation,
auditory neuropathy
Alive by age
2 yr; required
respiratory
support
Case 2 Arabic Yes Not known 6 mo M Hypotonia,
bulbar palsy
Not known 6 mo Hypotonia, bulbar palsy,
respiratory difﬁculties
Died, age 13 mo
Family 2
Case 3 European
ancestry
No Normal 16 mo F Progressive
bulbar palsy
16 mo Ventilated,
over last few mo
Anterior horn
neuropathy; Intact
cognitive development
Died, age < 3yr
Family 3
Case 4 European/
Asian
No Normal 9 mo M Breathing
problems
Yes 2 yr Multiple cranial nerve
involvement
Died, age 2 yr
Family 4
Case 5 Pakistani Yes Normal 12 yr F VII nerve palsy,
deafness
12 yr Stridor on exercise,
age 28 yr
Progressive muscle
weakness
Alive, age 36 yr
Case 6 Pakistani Yes Normal 12 yr F Deafness, Tongue
wasting and
fasciculations
12 yr, cochlear
implant, age 15 yr
Stridor on
exercise, age 21 yr
Poor balance, proximal
muscle group weakness
Alive, age 29 yr
Family 5
Case 7 Pakistani Yes Normal 5 yr F Tongue
fasciculations,
facial palsy,
7 yr, aided 13 yr Progressive muscle
weakness and wasting,
external ophthalmoplegia
Died, age 14 yr
Family 6
Case 8 European No Normal 3 mo F Breathing
difﬁculties,
weakness
Yes 3 mo General weakness, ﬂaccid Died, age 11 mo
Family 7
Case 9 European No Normal Second
decade
M Multiple
peripheral
neuropathy
Yes No Progressive weakness,
muscle wasting and
truncal ataxia
Alive, age 57 yr
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Table 2. Mutations Found in Patients with BVVLS
Case Ethnic Origin Consanguinity Number of Affect Cases Nucleotide Change Amino Acid Change Location
1, 2 Arabic Y 2 c.1048T>A
c.1325_1326 delTG
p.L350M
p.L442RfsX35
Exon 3
Exon 5
3 European ancestry N 1 c.211G>T p.E71X Exon 2
4 European/Asian N 1 c.639C>G p.Y213X Exon 3
5, 6 Pakistani Y 2 c.394C>T p.R132W Exon 2
7 Pakistani Y 1 c.670T>C p.F224L Exon 3
8 European N 1 c.1371C>G p.F457L Exon 5
9 European N 1 c.106G>A, c.1237T>C p.E36K, p.V413A Exon 2, Exon 5Cases 5 and 6 are two siblings of a consanguineous Pak-
istani couple, who presented in early childhood on the
background of previously normal motor and cognitive
development. Careful exploration of the previous medical
history, however, raised the possibility of mild early respi-
ratory difﬁculties upon exercise. They both have had
a slow progressive course and are alive in their late twenties
and thirties, respectively.
Case 7 is one of four siblings of a consanguineous Pakis-
tani family, who were reported by Dipti et al. in 2005.6
Patient 9 developed the condition in his early twenties.
He is now in his ﬁfties and is still able to walk a short
distance with a stick. He has signiﬁcant muscle wasting,
truncal ataxia, and progressive sensorineural deafness,
but he does not have respiratory compromise. There is
a similarly affected brother who has not been available
for testing at this stage. Two sisters died in childhood
and had a clinical picture consistent with BVVLS.
DNA from the proband and the affected relative was
used for autozygositymapping with the use of the Illumina
Human CNV370 array. Only one region of shared homozy-
gosity longer than 1 Mb was identiﬁed: a 2.25 Mb region
on chromosome 20p13, containing 44 genes (172128–
2459030).
Several genes from the candidate region were sequenced
by Sanger dideoxy sequencing. We elected to ﬁrst analyze
NRSN2 (MIM 610666), TCF15 (MIM 601010), SNPH (MIM
604942), SDCBP2, and NSFL1C because of their high
expression in the brain, followed by sequencing of the
remaining exons within the target region. A homozygous
2 bp frameshift mutation was identiﬁed in exon 5 of
C20orf54 (Table 2). The mutation was also homozygous in
the affected cousin and was heterozygous in the proband’s
parents and healthy sibling. Themutation was predicted to
cause a frameshift resulting in amutant protein built of 504
amino acids, 35 residues longer than the wild-type protein
(Figure S1, available online). A second change was also
found in these two patients (c.1048T>A [p.L350M]). The
change is not a known SNPbut is unlikely to be pathogenic,
because it is predicted to be tolerated by SIFT9 and L350 is
not highly conserved, even among mammalian orthologs.
DNAfromanadditional sevenpatients (cases3–9,Table1)
was sequenced for the entire C20orf54. HomozygousThe Amerinonsense mutations were found in cases 3 and 4 (Table 2),
whereas both siblings fromfamily 4 (cases 5 and6) andcases
7and8harboredhomozygousmissensemutations (Table2).
Conservation of the residues involved in missense muta-
tionsacrossa rangeof species is shown inFigure1. Evidently,
these three residues are highly conserved (although R132
can also be Q). Residue R132 is predicted to occur in an
intracellular loop, F224 is predicted to be part of transmem-
brane helix 6, and F457 is predicted to occur in the extracel-
lular tail. All three are predicted to be deleterious by SIFT.
Case 9 was found to carry two heterozygous missense
mutations (Table 2). p.E36K is predicted to be deleterious
by SIFT, whereas the other, p.V413A, is predicted to be
tolerated. This would be in keeping with the somewhat
milder phenotype in this patient.
With the exception of case 9 (compound heterozygote),
all patients reported here were homozygous for their
respective mutations. Cases 1, 2, 3, 5, 6, and 7 were also
homozygous for all 18 polymorphisms covered by the
sequenced regions, suggesting a common origin for each
mutation (as expected for the consanguineous families 1,
4, and 5). However, cases 4 and 8 were heterozygous for
one or more SNPs, indicating that the same mutation has
occurred on more than one background (Table S1).
None of the mutations identiﬁed in our cohort was
found in 210 control chromosomes, demonstrating that
they are uncommon in the general population (allele
frequency below 1%, 80% power10).
C20orf54 is a 5 exon gene located in 20p13 within our
candidate region. It comprises 11 predicted transmem-
brane helices and is therefore likely to be a transmembrane
protein. C20orf54 is highly conserved in evolutionary
terms, sharing 59% identity with chicken and zebraﬁsh
and 36% with C. elegans (homologene).
Evidence of a possible function for this protein has
recently come from a study by Yamamoto et al., who spec-
ulate that the rat ortholog (rRFT2) is a transporter of ribo-
ﬂavin in the small intestine.11 The human ortholog,
C20orf54, shares 83% similarity with rRFT2; hence, they
suggest renaming the gene RFT2.
Riboﬂavin deﬁciency has a clinical picture very different
from that of BVVLS; therefore, the postulated function of
the protein is unlikely to play a substantive role in diseasecan Journal of Human Genetics 86, 485–489, March 12, 2010 487
Figure 1. Multiple Alignment of
C20orf54 Protein Sequence
The C20orf54 protein sequence with the
six missense mutations (p.E36K,
p.R132W, p.F224L, p.L350M, p.V413A,
and p.F457L) is shown in eight orthologs.
The mutations p.E36K and p.V413A are
found in case 9 (Table 1), who is a com-
pound heterozygote. The alignment was
performed with ClustalW2, and the Gen-
Bank accession numbers are NP_212134.
3, XP_001152229.1, XP_001112427.1,
XP_542938.2, XP_001916183.1, NP_
001032275.1, NP_081448.2, and NP_
001033515.mechanism. Riboﬂavin is essential for synthesis of Flavin
Adenine Dinucleotide (FAD) and Flavin Mononucleotide
(FMN). Both operate as cofactors for a number of biological
processes involved in energy metabolism. Flavoproteins
have been implicated as having signal transduction roles
in apoptosis12 and DNA repair.13 Flavins contribute to
oxidative stress through their ability to produce super-
oxide, as well as in the reduction of hydroperoxides by
forming parts of multi-redox-center enzymes, such as the
succinate and NADH dehydrogenases, xanthine oxidase/
dehydrogenase, cytochrome P450 systems, and nitric
oxide synthase.14 It is plausible that the protein has amain-
tenance function in the nervous system and that the
disease is precipitated by exhaustion of a pathway tightly
regulated by this protein.488 The American Journal of Human Genetics 86, 485–489, March 12, 2010The clinical similarity between
BVVLS syndrome and ALS has long
been recognized, suggesting that the
two conditions may be part of the
same spectrum. On the basis of
the limited evidence that C20orf54
product is involved in the synthesis
of molecules with pivotal role in cell
energy metabolism, it is tempting to
speculate that these conditions share
a common pathway. It is conceivable
that some cases of early-onset ALS,
especially of the familial type, may
be due to mutations in C20orf54,
and it is worthwhile exploring this
hypothesis by testing an appropriate
cohort of patients. A locus on 20p13
designated as ALS7 (MIM 608037),
which was identiﬁed by studying
a large dominant family with mul-
tiple affected individuals,15 over-
laps with C20orf54. However, the
absence of any symptomatic carriers
in our cohort makes it less likely
that heterozygous mutations in this
gene are associated with dominant
ALS.In conclusion, we have identiﬁed a gene that is highly
conserved across the evolutionary time scale. The function
of this gene in the nervous system is as yet unknown. We
have demonstrated that recessive mutations give rise
to BVVLS. The methodology used here to locate the causa-
tive gene conﬁrms the power of autozygosity mapping
together with targeted sequencing in identifying genes in
rare recessive disorders for which consanguineous families
are available.Supplemental Data
Supplemental Data include two ﬁgures and one table and can be
found with this article online at http://www.ajhg.org.
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